790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab

Abstract

BackgroundThe presence of CD1c (BDCA-1)+ (cDC2) and CD141 (BDCA-3)+ (cDC1) conventional dendritic cells (myDC) in the tumor microenvironment (TME) is a necessary prerequisite to induce an effector CD8+ T cell...